Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022. Second Quarter 2022 Results: Revenue of $125.3 million, versus $153.6 million in Q2 2021 Billable tests delivered over 1.3 million, versus 1.6 million in Q2 2021 Core...